This pilot study will provide data essential for designing a larger trial to test the hypothesis that telmisartan treatment of obese children with insulin resistance and hypertension will result in improved insulin levels and systolic blood pressure.
Secondary outcome measures will include the effects of telmisartan on total cholesterol, triglyceride, HDL and LDL levels, body mass index (BMI), and body fat distribution.
10 Years to 18 Years (Child, Adult)
September 16, 2005
February 14, 2007
Stanford Medical Center Stanford, California, United States
† Study has passed its completion date and status has not been verified in more than two years.